Shorla Pharma raised €7.4m
Shorla Pharma focus on improving existing treatments which are limited, in short supply or not suitable.
“We’re very familiar with the oncology world and have worked very closely with clinicians all over the world to identify where the biggest needs are.”
Shorla Pharma develop and commercialize innovative oncology drugs for women’s and pediatric cancers. They focus on indications where existing treatments are limited, in shortage or inadequate for the target population.
Shorla Pharma is addressing the need in the oncology area for treatments that overcome difficulties with how some cancer drugs are administered.
One aspect that Shorla Pharma have already improved is in the area of tablets. Children on certain types of medication can find it very difficult to physically swallow the prescribed tablet so parents end up opening the capsules and mixing the contents into a drink such as juice to get the child to take it, this is dangerous for all involved and also alters the tablet so it will not work as well.
Shorla Pharma redeveloped this from a difficult-to-swallow capsule into an oral solution.
In 2020, Shorla Pharma was named Local Enterprise of the Year at the ‘Irish Times’ awards.
Shorla Pharma has since expanded into Boston to lead the transatlantic expansion and commercial strategy of the company. Shorla prepares to launch its first U.S. product, SH-111, a treatment for children with T-cell Leukemia. Shorla Pharma has partnered with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment
“This is an important step in our commercialization planning. As a company breaking new ground in the treatment of cancers, with our first product targeted for launch later in the year, we believe now is the right time to establish our U.S. operations.”
Sign up for up for our newsletter to receive updates on business, careers, and investment in Ireland South East.
ISE Development Office
Enterprise Ireland Building
Waterford Industrial Park